Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F182112 + isatuximab + lenalidomide
- Development stage
- Phase 2
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
F182112 + isatuximab + lenalidomide is an investigational triplet combination regimen being evaluated for the treatment of newly diagnosed multiple myeloma. The combination consists of F182112, a recombinant humanized bispecific T-cell engager (BiTE) antibody targeting both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells; isatuximab, an anti-CD38 monoclonal antibody; and lenalidomide, an immunomodulatory drug. This regimen is being investigated in a prospective, single-center, single-arm, exploratory pilot clinical trial (NCT07828522) in transplant-eligible patients with newly diagnosed multiple myeloma to evaluate its safety, feasibility, and preliminary efficacy, including deep responses and minimal residual disease (MRD) negativity.
- Other names
- F182112 plus isatuximab and lenalidomideF-182112 plus isatuximab and lenalidomideF 182112 plus isatuximab and lenalidomideF182112, isatuximab, and lenalidomide
02
Targets
CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)BCMA (Tumor necrosis factor receptor superfamily member 17)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on F182112 + isatuximab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F182112 + isatuximab + lenalidomide.